IDWeek 2025 heads to Atlanta October 19–22 with cutting-edge sessions on AMR, AI, vaccines, HIV, pediatrics, and global health challenges. The infectious diseases community will gather in Atlanta from ...

P atients with well-controlled inflammatory arthritis (IA) who abruptly discontinue adalimumab are likely to have higher flare rates than those who taper this medication or another tumor necrosis ...

In part 3 of this 7-part Special Report, the discussion turns to the importance of diagnostic stewardship, with Denise Heaney, PhD, underscoring how FDA-cleared assays—ranging from at-home sample ...

The clinical report replaces a 2010 report, as food allergy impacts up to 10% of children, with anaphylaxis estimated to occur in 1 in 15 schools per year. Authors note that accurate diagnosis is the ...

Richard Auchus, MD, PhD, discusses how crinecerfont is improving CAH care and easing the transition from pediatric to adult management. Since its FDA approval on December 13, 2024, crinecerfont ...

As team sports ramp up this fall, pediatricians can expect the return of a familiar question from parents: “What should my child eat before the big game?” Sports nutrition is not just a modified ...

The FDA has approved Viatris Inc’s iron sucrose injection, USP, for the treatment of iron deficiency anemia (IDA) in adult and pediatric patients 2 years and older with chronic kidney disease (CKD).

Of the 253 influenza-related pediatric deaths through June 21, 2025, 42.7% occurred in children without a high-risk medical condition. The American Academy of Pediatrics (AAP), an organization made up ...

A new polygenic risk score enhances obesity risk prediction from childhood to adulthood, offering new insights for early intervention and prevention strategies. An international team of researchers ...

A study reveals declining US neonatal mortality overall, yet highlights rising deaths from fetal malnutrition, emphasizing ongoing disparities in neonatal health outcomes.

Pelthos Therapeutics has launched berdazimer (Zelsuvmi) topical gel, 10.3%, for the treatment of molluscum contagiosum in adults and pediatric patients aged 1 year and older, according to a company ...

Specifically, the ACIP voted 5-2 to recommend clesrovimab (Enflonsia; Merck), which was approved by the FDA on June 9, 2025, for infants aged 8 months and younger who are not protected by a maternal ...